Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Thursday, February 20, 2025 2 min read
Key Takeaway: Kiniksa Pharmaceuticals announced that it will host a conference call on February 25, 2025, to report its fourth quarter and full year 2024 financial results. The call will include details on recent portfolio execution and will be available via live webcast. Kiniksa, focused on developing therapies for cardiovascular and autoimmune diseases, emphasizes its commitment to addressing unmet medical needs. Interested individuals can register for the call and access a replay on the company’s website afterward.
Market Sentiment Analysis
POSITIVE FACTORS
Kiniksa Pharmaceuticals is set to report their financial results, indicating transparency and engagement with investors.
The company's focus on novel therapies for unmet medical needs showcases their commitment to innovation in biopharmaceuticals.
The upcoming conference call provides an opportunity for investors to learn about recent portfolio execution.
Full Press Release Details
LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular and autoimmune indications. Kiniksa’s portfolio assets are based on strong biologic rationale or validated mechanisms and offer the potential for differentiation. For more information, please visit www.kiniksa.com.